



5 July 2018

**To whom it may concern**

In the European Union, two quadrivalent meningococcal vaccines protecting against serogroups A, C, Y and W135 has been licensed for use by the European Medicines Agency (EMA).

Menveo<sup>®</sup> was first licensed in March 2010 and renewed in December 2014. In children  $\geq 2$  years and in adults, one dose is recommended.

Nimenrix<sup>®</sup> was first licensed in April 2012 and renewed in February 2017. In children  $\geq 1$  years and in adults, one dose is recommended.

In Denmark, Statens Serum Institut (SSI) is responsible for purchase and distribution of vaccines to the population. Normally, SSI holds both the above described licensed products in stock.

Due to a national short-out, Menveo<sup>®</sup> is presently not available why individuals with a need for protection against meningococcal disease will be vaccinated with Nimenrix<sup>®</sup> which is considered equally protective in adults.

The short-out on Menveo<sup>®</sup> is expected to last to sometime in the fall of 2018.

Best regards,

Peter Henrik Andersen  
Senior Medical Officer  
Department of Infectious Disease Epidemiology and Prevention  
Artillerivej 5  
DK-2300 Copenhagen S  
Denmark  
Ph. +45 3268 3265  
Email: pea@ssi.dk